Express News | Kiromic Biopharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Moomoo 24/7Apr 24 08:08 ET
Kiromic Biopharma Outlines Vision in Stakeholder Meetings
TipRanksApr 19 16:43 ET
Kiromic BioPharma Files to Withdraw Registration Statement
Seeking AlphaApr 10 17:19 ET
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
PDF Version Favorable Safety and Tolerability also Observed HOUSTON--(BUSINESS WIRE)--Mar. 19, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy res
Kiromic BioPharmaMar 19 00:00 ET
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Yahoo FinanceMar 8 08:35 ET
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Yahoo FinanceMar 5 08:35 ET
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
PDF Version Third Patient Enrolled in Deltacel-01 Completes Treatment HOUSTON--(BUSINESS WIRE)--Mar. 1, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces that Vi
Kiromic BioPharmaMar 1 00:00 ET
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
PDF Version Live and Archived Fireside Chat Available at VirtualInvestorConferences.com HOUSTON--(BUSINESS WIRE)--Feb. 28, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company"
Kiromic BioPharmaFeb 28 00:00 ET
Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth
TipRanksFeb 14 16:45 ET
Results From First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
PDF Version Second Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel for the Treatment of Non-Small Cell Lung Cancer HOUSTON--(BUSINESS WIRE)--Feb. 14, 2024
Kiromic BioPharmaFeb 14 00:00 ET
Kiromic BioPharma Reports Favorable Early Efficacy Results From First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
PDF Version Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated HOUSTON--(BUSINESS WIRE)--Jan. 29, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or th
Kiromic BioPharmaJan 29 00:00 ET
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data From First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
PDF Version Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco HOUSTON--(BUSINESS WIRE)--Jan. 5, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kirom
Kiromic BioPharmaJan 5 00:00 ET
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel for the Treatment of Non-Small Cell Lung Cancer
PDF Version Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 HOUSTON--(BUSINESS WIRE)--Dec. 14, 2023-- Kiromi
Kiromic BioPharmaDec 14, 2023 00:00 ET
Kiromic BioPharma Announces Deltacel Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
PDF Version Company is Activating Additional Clinical Trial Sites Across the U.S. HOUSTON--(BUSINESS WIRE)--Nov. 9, 2023--Kiromic BioPharma, Inc. (OTC PINK: KRBP) ("Kiromic" or the "Company"), a
Kiromic BioPharmaNov 9, 2023 00:00 ET
GRI Bio, HealthStream, Kiromic BioPharma Among Healthcare Movers
Seeking AlphaSep 14, 2023 10:00 ET
Kiromic Biopharma Shares Suspended From Trading on Nasdaq
Kiromic BioPharma (KRBP) said Wednesday that it has been notified that its common shares were suspended from trading on the Nasdaq Capital Market, effective Sept. 14, due to failure to demonstrate com
MT NewswiresSep 14, 2023 06:36 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersInfinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% o
BenzingaSep 13, 2023 17:31 ET
Kiromic BioPharma to List on OTC Pink Sheets After Nasdaq Trading Suspension
Seeking AlphaSep 13, 2023 16:50 ET
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
PDF Version KRBP Suspended from Trading on Nasdaq HOUSTON--(BUSINESS WIRE)--Sep. 13, 2023-- Kiromic BioPharma (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated bioth
Kiromic BioPharmaSep 13, 2023 00:00 ET
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 46 stocks hit new 52-week lows. Key Facts About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Moderna (NASDAQ:MRNA).American Rebel Holdings (NASDAQ
BenzingaAug 1, 2023 15:06 ET
No Data
No Data